26
|
Lyndon D, Davagnanam I, Wilson D, Jichi F, Merwick A, Bolsover F, Jager HR, Cipolotti L, Wheeler-Kingshott C, Hughes D, Murphy E, Lachmann R, Werring DJ. MRI-visible perivascular spaces as an imaging biomarker in Fabry disease. J Neurol 2020; 268:872-878. [PMID: 33078310 PMCID: PMC7914182 DOI: 10.1007/s00415-020-10209-7] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2020] [Revised: 08/30/2020] [Accepted: 09/02/2020] [Indexed: 12/02/2022]
Abstract
Introduction Fabry disease (FD) is an X-linked lysosomal storage disorder resulting in vascular glycosphingolipid accumulation and increased stroke risk. MRI findings associated with FD include white matter hyperintensities (WMH) and cerebral microbleeds (CMBs), suggesting the presence of cerebral small vessel disease. MRI-visible perivascular spaces (PVS) are another promising marker of small vessel disease associated with impaired interstitial fluid drainage. We investigated the association of PVS severity and anatomical distribution with FD.
Patients and methods We compared patients with genetically proven FD to healthy controls. PVS, WMH, lacunes and CMBs were rated on standardised sequences using validated criteria and scales, blinded to diagnosis. A trained observer (using a validated rating scale), quantified the total severity of PVS. We used logistic regression to investigate the association of severe PVS with FD. Results We included 33 FD patients (median age 44, 44.1% male) and 20 healthy controls (median age 33.5, 50% male). Adjusting for age and sex, FD was associated with more severe basal ganglia PVS (odds ratio (OR) 5.80, 95% CI 1.03–32.7) and higher total PVS score (OR 4.03, 95% CI 1.36–11.89). Compared with controls, participants with FD had: higher WMH volume (median 495.03 mm3 vs 0, p = 0.0008), more CMBs (21.21% vs none, p = 0.04), and a higher prevalence of lacunes (21.21% vs. 5%, p = 0.23). Conclusions PVS scores are more severe in FD than control subjects. Our findings have potential relevance for FD diagnosis and suggest that impaired interstitial fluid drainage might be a mechanism of white matter injury in FD.
Collapse
|
27
|
Odin IS, Cao S, Hughes D, Zamaratskii EV, Zarubin YP, Purygin PP, Golovanov AA, Zlotskii SS. Synthesis of New N-Acyl-1,2,3-triazole Chalcones and Determination of Their Antibacterial Activity. DOKLADY CHEMISTRY 2020. [DOI: 10.1134/s0012500820360021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
28
|
Kirchner S, Lei V, Coates M, Handfield C, Corcoran D, Ling X, Shannon J, Coutinho Goulart Borges Mariottoni PR, Hughes D, Waters D, Dzirasa K, MacLeod A. 814 Circadian factors BMAL1 and CLOCK control transcriptional innate antiviral immunity programs in response to skin wounding. J Invest Dermatol 2020. [DOI: 10.1016/j.jid.2020.03.829] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
29
|
Edmondson C, Westrupp N, Seddon P, Olden C, Wallis C, Dawson C, Brodlie M, Baxter F, McCormick J, Connon M, Blaikie L, Thursfield R, Brown L, Price A, Fleischer E, Hughes D, Barrett P, Mak D, Wallenburg J, Brownlee K, Alton E, Bush A, Davies J. ePS5.09 CLInical Monitoring and Biomarkers to stratify severity and predict outcomes in children with cystic fibrosis (CLIMB-CF): usability results from our feasibility study. J Cyst Fibros 2020. [DOI: 10.1016/s1569-1993(20)30328-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
30
|
Costello M, Murphy R, Judge C, Ruttledge S, Gorey S, Loughlin E, Hughes D, Nolan A, O’Donnell MJ, Canavan M. Effect of non‐vitamin‐K oral anticoagulants on stroke severity compared to warfarin: a meta‐analysis of randomized controlled trials. Eur J Neurol 2020; 27:413-418. [DOI: 10.1111/ene.14134] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/06/2019] [Accepted: 11/22/2019] [Indexed: 11/29/2022]
|
31
|
Bicho Augusto JA, Nordin S, Kozor R, Vijapurapu R, Knott K, Ramaswami U, Geberhiwot TD, Steeds RP, Baig S, Hughes D, Moon JC. P340Inflammatory cardiomyopathy in Fabry disease. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0174] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Fabry disease (FD) is an X-linked lysosomal storage disorder caused by mutations in α-galactosidase A. Cardiovascular magnetic resonance (CMR) has helped unveil the pathogenesis of Fabry cardiomyopathy: sphingolipid storage (low T1 mapping values), left ventricular hypertrophy (LVH) and myocardial fibrosis with late gadolinium enhancement (LGE) characteristically present in the basal inferolateral (BIFL) wall. Recent evidence has suggested that the LGE may be inflammation and oedema as part of this pathogenic process.
Purpose
To assess the presence of inflammation in patients with FD using T2 mapping (for oedema/inflammation) supported by blood troponin levels (showing myocyte death and by inference inflammation).
Methods
A multi-centre international study in gene positive FD patients using CMR and blood biomarkers. All participants underwent CMR at 1.5 T. Native T1 and T2 mapping were performed. The T1 mapping sequence was MOLLI with sampling scheme in seconds. LGE used a phase sensitive inversion recovery sequence. Global longitudinal 2D strain (GLS) values were obtained using feature tracking analysis. Blood high-sensitivity troponin T (hsTnT) was measured on the same day.
Results
100 FD patients (age 43.8±1.3 years, 42% male) were included. 45% had LVH, 35% LGE. Low T1 mapping (normal <943ms) was found in 49% and 33% had high hsTnT values (normal <15ng/L). Mean T2 mapping values were 52.6±0.6ms in the BIFL wall and 49.5±0.3ms in the remote myocardium/septum (p<0.001, normal <53ms). T2 values in the BIFL wall were significantly higher among patients with LGE (58.2±6.1ms vs 49.2±3.1ms, p<0.001, Figure 1). In a per-segment analysis of 1600 segments, higher T2 values correlated positively with percentage of LGE per segment (r=0,262, p<0.001), T1 values (r=0,205, p<0.001), maximum wall thickness (r=0,253, p<0.001) and GLS values (r=0,212, p<0.001). HsTnT values were higher among patients with LGE (median of 31 vs 3ng/L in patients without LGE, p<0.001). There was a strong positive correlation between T2 values in the BIFL wall and ln(hsTnT) (r=0.776, p<0.001, Figure 2). The strongest predictor of increased hsTnT in multivariate analysis (age, sex, LVH, septum T1, T2 in the BIFL, GLS, LGE) was T2 in the BIFL wall (β=0.4, p=0.001).
Conclusions
Cardiac involvement in FD goes beyond storage (low T1 values). When LGE is present, this is almost always associated with a high T2 and troponin elevation supporting FD as a chronic inflammatory cardiomyopathy. Initial reports of LGE being fibrosis are too simplistic – LGE in FD appears to have a significant chronic inflammation/oedema component.
Collapse
|
32
|
Knight SR, Pearson R, Kiely C, Lee G, MacDonald AJ, Macdonald A, Ravi F, Ramsay G, Sellars H, Macleod C, Robertson J, Oliver W, Ventham N, Turnbull A, Dunstan E, Webber R, Norton A, Shearer R, Clement K, Kilkenny J, Lim J, Wilson M, Littlechild J, Joy M, Donoghue C, Mansouri D, Dreyer B, Stevenson R, Clark L, Yong K, Fostyk N, Tummon R, Jack R, Boland M, Speake D, Savioli F, Hughes D. Patient consent in the post-Montgomery era: A national multi-speciality prospective study. Surgeon 2019; 17:277-283. [DOI: 10.1016/j.surge.2018.08.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2018] [Revised: 08/15/2018] [Accepted: 08/25/2018] [Indexed: 11/26/2022]
|
33
|
Libeyre P, Schild T, Bruton A, Cormany C, Dolgetta N, Gaxiola E, Jong C, Mitchell N, Evans D, Levesy B, Bedakihale V, Garcia Sanchez P, Mariani A, Okugawa R, Reiersen W, Martovetsky N, Everitt D, Hughes D, Reagan T, Freudenberg K, Hatfield D, Chae T, Vandergriff D, Sgobba S, Aviles I, Decool P, Vallet J, Nunio F. From manufacture to assembly of the ITER central solenoid. FUSION ENGINEERING AND DESIGN 2019. [DOI: 10.1016/j.fusengdes.2018.12.086] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
34
|
Murray H, Hodgkinson P, Hughes D. Remifentanil patient-controlled intravenous analgesia during labour: a retrospective observational study of 10 years’ experience. Int J Obstet Anesth 2019; 39:29-34. [DOI: 10.1016/j.ijoa.2019.05.012] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/23/2018] [Revised: 03/13/2019] [Accepted: 05/27/2019] [Indexed: 11/16/2022]
|
35
|
Bicho Augusto JA, Nordon S, Kozor R, Vijapurapu R, Knott K, Hughes R, Rosmini S, Ramaswami U, Geberhiwot T, Steeds RP, Baig S, Hughes D, Moon JC. 323Inflammatory cardiomyopathy in Fabry disease. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez102.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
36
|
Smith L, Hughes D, Chan HF, Johnson K, Bray J, Rodgers O, Collier G, Norquay G, Biancardi A, Hughes P, Kotecha S, Wildman M, West N, Horsley A, Marshall H, Wild J. WS17-2 The sensitivity of MRI to detect both functional and structural lung abnormalities in sub-clinical cystic fibrosis. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30218-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
37
|
Knott K, Augusto JB, Nordin S, Kozor R, Camaioni C, Xue H, Hughes RK, Manisty C, Brown LAE, Ramaswami U, Hughes D, Kellman P, Plein S, Moon JC. 304Quantitative perfusion mapping in Fabry disease. Eur Heart J Cardiovasc Imaging 2019. [DOI: 10.1093/ehjci/jez119.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
38
|
Edmondson C, Westrupp N, Seddon P, Olden C, Wallis C, Dawson C, Brodlie M, Baxter F, McCormick J, Connon M, Blaikie L, Thursfield R, Brown L, Price A, Fleischer E, Hughes D, Barrett P, Haider S, Fontanella S, Mak D, Wallenburg J, Brownlee K, Alton E, Bush A, Davies J. ePS5.07 CLInical Monitoring and Biomarkers to stratify severity and predict outcomes in children with cystic fibrosis (CLIMB-CF): results from the feasibility study. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30285-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
39
|
Horný M, Cronan J, Duszak R, Spies J, Newsome J, Carlos R, Hughes D, Xing M, Kokabi N, Cronan J. 03:18 PM Abstract No. 260 Comparison of direct procedural and episode of care cost for invasive therapies in management of uterine fibroid embolization and associated patient-incurred financial burden. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
40
|
Cronan J, Horný M, Spies J, Newsome J, Carlos R, Hughes D, Duszak R, Xing M, Kokabi N, Cronan J. 03:27 PM Abstract No. 261 National variation in management of symptomatic uterine fibroids in contemporary clinical practice. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.323] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
41
|
Chiarello M, Duszak R, Hemingway J, Hughes D, Patel A, Rosenkrantz A. 03:09 PM Abstract No. 142 Market shifts in transcatheter dialysis conduit procedures in the Medicare population: a 15-year national and state-level analysis. J Vasc Interv Radiol 2019. [DOI: 10.1016/j.jvir.2018.12.192] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
|
42
|
Orchard J, Orchard J, Toresdahl B, Asif I, Hughes D, La Gerche A, Semsarian C. Cardiovascular Screening of Elite Athletes by Sporting Organisations in Australia: A Survey of Chief Medical Officers. Heart Lung Circ 2019. [DOI: 10.1016/j.hlc.2019.06.528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
43
|
Mullin S, Hughes D, Mehta A, Schapira AHV. Neurological effects of glucocerebrosidase gene mutations. Eur J Neurol 2018; 26:388-e29. [PMID: 30315684 PMCID: PMC6492454 DOI: 10.1111/ene.13837] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2018] [Accepted: 10/09/2018] [Indexed: 01/08/2023]
Abstract
The association between Gaucher disease (GD) and Parkinson disease (PD) has been described for almost two decades. In the biallelic state (homozygous or compound heterozygous) mutations in the glucocerebrosidase gene (GBA) may cause GD, in which glucosylceramide, the sphingolipid substrate of the glucocerebrosidase enzyme (GCase), accumulates in visceral organs leading to a number of clinical phenotypes. In the biallelic or heterozygous state, GBA mutations increase the risk for PD. Mutations of the GBA allele are the most significant genetic risk factor for idiopathic PD, found in 5%–20% of idiopathic PD cases depending on ethnicity. The neurological consequences of GBA mutations are reviewed and the proposition that GBA mutations result in a disparate but connected range of clinically and pathologically related neurological features is discussed. The literature relating to the clinical, biochemical and genetic basis of GBA PD, type 1 GD and neuronopathic GD is considered highlighting commonalities and distinctions between them. The evidence for a unifying disease mechanism is considered.
Collapse
|
44
|
Dobra R, Edmondson C, Hughes D, Martin I, Davies JC. Potentiators and Correctors in Paediatric Cystic Fibrosis Patients: A Narrative Review. Paediatr Drugs 2018; 20:555-566. [PMID: 30328089 DOI: 10.1007/s40272-018-0315-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Cystic fibrosis is the most common inherited condition in the Caucasian population and is associated with significantly reduced life expectancy. Recent advances in treatment have focussed on addressing the underlying cause of the condition, the defective production, expression and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein. Several drugs with different modes of action have produced promising results in clinical trials, and some have been incorporated into routine clinical care for specific patients in many countries worldwide. Further trials continue to explore the safety and efficacy of these drugs in the youngest age groups and to search for more effective therapies to treat the most common disease-causing gene mutations in an ever-expanding drug pipeline. As evidence mounts for the early onset of disease in young patients, the prospect of introducing disease-modifying therapy in early life becomes more pertinent, although the cost implications of these expensive drugs are significant. In this review, we summarise these new therapy advances and review those currently being explored in clinical trials.
Collapse
|
45
|
Rogers M, Burke L, Vlahovich N, Lovell G, Pyne D, Lundy B, Appaneal R, Halson S, West N, Welvaert M, Hughes D, Waddington G, Drew M. Prevalence of variables related to RED-S in Australian elite and pre-elite female athletes. J Sci Med Sport 2018. [DOI: 10.1016/j.jsams.2018.09.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Agnes P, Albuquerque IFM, Alexander T, Alton AK, Araujo GR, Asner DM, Ave M, Back HO, Baldin B, Batignani G, Biery K, Bocci V, Bonfini G, Bonivento W, Bottino B, Budano F, Bussino S, Cadeddu M, Cadoni M, Calaprice F, Caminata A, Canci N, Candela A, Caravati M, Cariello M, Carlini M, Carpinelli M, Catalanotti S, Cataudella V, Cavalcante P, Cavuoti S, Cereseto R, Chepurnov A, Cicalò C, Cifarelli L, Cocco AG, Covone G, D'Angelo D, D'Incecco M, D'Urso D, Davini S, De Candia A, De Cecco S, De Deo M, De Filippis G, De Rosa G, De Vincenzi M, Demontis P, Derbin AV, Devoto A, Di Eusanio F, Di Pietro G, Dionisi C, Downing M, Edkins E, Empl A, Fan A, Fiorillo G, Fomenko K, Franco D, Gabriele F, Gabrieli A, Galbiati C, Garcia Abia P, Ghiano C, Giagu S, Giganti C, Giovanetti GK, Gorchakov O, Goretti AM, Granato F, Gromov M, Guan M, Guardincerri Y, Gulino M, Hackett BR, Hassanshahi MH, Herner K, Hosseini B, Hughes D, Humble P, Hungerford EV, Ianni A, Ianni A, Ippolito V, James I, Johnson TN, Kahn Y, Keeter K, Kendziora CL, Kochanek I, Koh G, Korablev D, Korga G, Kubankin A, Kuss M, La Commara M, Lai M, Li X, Lisanti M, Lissia M, Loer B, Longo G, Ma Y, Machado AA, Machulin IN, Mandarano A, Mapelli L, Mari SM, Maricic J, Martoff CJ, Messina A, Meyers PD, Milincic R, Mishra-Sharma S, Monte A, Morrocchi M, Mount BJ, Muratova VN, Musico P, Nania R, Navrer Agasson A, Nozdrina AO, Oleinik A, Orsini M, Ortica F, Pagani L, Pallavicini M, Pandola L, Pantic E, Paoloni E, Pazzona F, Pelczar K, Pelliccia N, Pesudo V, Picciau E, Pocar A, Pordes S, Poudel SS, Pugachev DA, Qian H, Ragusa F, Razeti M, Razeto A, Reinhold B, Renshaw AL, Rescigno M, Riffard Q, Romani A, Rossi B, Rossi N, Sablone D, Samoylov O, Sands W, Sanfilippo S, Sant M, Santorelli R, Savarese C, Scapparone E, Schlitzer B, Segreto E, Semenov DA, Shchagin A, Sheshukov A, Singh PN, Skorokhvatov MD, Smirnov O, Sotnikov A, Stanford C, Stracka S, Suffritti GB, Suvorov Y, Tartaglia R, Testera G, Tonazzo A, Trinchese P, Unzhakov EV, Verducci M, Vishneva A, Vogelaar B, Wada M, Waldrop TJ, Wang H, Wang Y, Watson AW, Westerdale S, Wojcik MM, Wojcik M, Xiang X, Xiao X, Yang C, Ye Z, Zhu C, Zichichi A, Zuzel G. Constraints on Sub-GeV Dark-Matter-Electron Scattering from the DarkSide-50 Experiment. PHYSICAL REVIEW LETTERS 2018; 121:111303. [PMID: 30265123 DOI: 10.1103/physrevlett.121.111303] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/15/2018] [Revised: 07/16/2018] [Indexed: 06/08/2023]
Abstract
We present new constraints on sub-GeV dark-matter particles scattering off electrons based on 6780.0 kg d of data collected with the DarkSide-50 dual-phase argon time projection chamber. This analysis uses electroluminescence signals due to ionized electrons extracted from the liquid argon target. The detector has a very high trigger probability for these signals, allowing for an analysis threshold of three extracted electrons, or approximately 0.05 keVee. We calculate the expected recoil spectra for dark matter-electron scattering in argon and, under the assumption of momentum-independent scattering, improve upon existing limits from XENON10 for dark-matter particles with masses between 30 and 100 MeV/c^{2}.
Collapse
|
47
|
Agnes P, Albuquerque IFM, Alexander T, Alton AK, Araujo GR, Asner DM, Ave M, Back HO, Baldin B, Batignani G, Biery K, Bocci V, Bonfini G, Bonivento W, Bottino B, Budano F, Bussino S, Cadeddu M, Cadoni M, Calaprice F, Caminata A, Canci N, Candela A, Caravati M, Cariello M, Carlini M, Carpinelli M, Catalanotti S, Cataudella V, Cavalcante P, Cavuoti S, Cereseto R, Chepurnov A, Cicalò C, Cifarelli L, Cocco AG, Covone G, D'Angelo D, D'Incecco M, D'Urso D, Davini S, De Candia A, De Cecco S, De Deo M, De Filippis G, De Rosa G, De Vincenzi M, Demontis P, Derbin AV, Devoto A, Di Eusanio F, Di Pietro G, Dionisi C, Downing M, Edkins E, Empl A, Fan A, Fiorillo G, Fomenko K, Franco D, Gabriele F, Gabrieli A, Galbiati C, Garcia Abia P, Ghiano C, Giagu S, Giganti C, Giovanetti GK, Gorchakov O, Goretti AM, Granato F, Gromov M, Guan M, Guardincerri Y, Gulino M, Hackett BR, Hassanshahi MH, Herner K, Hosseini B, Hughes D, Humble P, Hungerford EV, Ianni A, Ianni A, Ippolito V, James I, Johnson TN, Kahn Y, Keeter K, Kendziora CL, Kochanek I, Koh G, Korablev D, Korga G, Kubankin A, Kuss M, La Commara M, Lai M, Li X, Lisanti M, Lissia M, Loer B, Longo G, Ma Y, Machado AA, Machulin IN, Mandarano A, Mapelli L, Mari SM, Maricic J, Martoff CJ, Messina A, Meyers PD, Milincic R, Mishra-Sharma S, Monte A, Morrocchi M, Mount BJ, Muratova VN, Musico P, Nania R, Navrer Agasson A, Nozdrina AO, Oleinik A, Orsini M, Ortica F, Pagani L, Pallavicini M, Pandola L, Pantic E, Paoloni E, Pazzona F, Pelczar K, Pelliccia N, Pesudo V, Pocar A, Pordes S, Poudel SS, Pugachev DA, Qian H, Ragusa F, Razeti M, Razeto A, Reinhold B, Renshaw AL, Rescigno M, Riffard Q, Romani A, Rossi B, Rossi N, Sablone D, Samoylov O, Sands W, Sanfilippo S, Sant M, Santorelli R, Savarese C, Scapparone E, Schlitzer B, Segreto E, Semenov DA, Shchagin A, Sheshukov A, Singh PN, Skorokhvatov MD, Smirnov O, Sotnikov A, Stanford C, Stracka S, Suffritti GB, Suvorov Y, Tartaglia R, Testera G, Tonazzo A, Trinchese P, Unzhakov EV, Verducci M, Vishneva A, Vogelaar B, Wada M, Waldrop TJ, Wang H, Wang Y, Watson AW, Westerdale S, Wojcik MM, Wojcik M, Xiang X, Xiao X, Yang C, Ye Z, Zhu C, Zichichi A, Zuzel G. Low-Mass Dark Matter Search with the DarkSide-50 Experiment. PHYSICAL REVIEW LETTERS 2018; 121:081307. [PMID: 30192596 DOI: 10.1103/physrevlett.121.081307] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/28/2018] [Indexed: 06/08/2023]
Abstract
We present the results of a search for dark matter weakly interacting massive particles (WIMPs) in the mass range below 20 GeV/c^{2} using a target of low-radioactivity argon with a 6786.0 kg d exposure. The data were obtained using the DarkSide-50 apparatus at Laboratori Nazionali del Gran Sasso. The analysis is based on the ionization signal, for which the DarkSide-50 time projection chamber is fully efficient at 0.1 keVee. The observed rate in the detector at 0.5 keVee is about 1.5 event/keVee/kg/d and is almost entirely accounted for by known background sources. We obtain a 90% C.L. exclusion limit above 1.8 GeV/c^{2} for the spin-independent cross section of dark matter WIMPs on nucleons, extending the exclusion region for dark matter below previous limits in the range 1.8-6 GeV/c^{2}.
Collapse
|
48
|
Vijapurapu R, Baig S, Wheeldon N, Hughes D, Jovanovic A, Woolfson P, Geberhiwot T, Steeds R. P1017A national study evaluating cardiac device implantation and usage in patients with Fabry disease. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p1017] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
49
|
Hughes D, Fedirko V, Umesh S, Schomburg L, Méplan C, Hybsier S, Riboli E, Jenab M. Selenium status and survival from colorectal cancer in the European prospective investigation of cancer and nutrition. Rev Epidemiol Sante Publique 2018. [DOI: 10.1016/j.respe.2018.05.142] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
|
50
|
Keating C, Hughes D, Mahony T, Cysneiros D, Ijaz UZ, Smith CJ, O'Flaherty V. Cold adaptation and replicable microbial community development during long-term low-temperature anaerobic digestion treatment of synthetic sewage. FEMS Microbiol Ecol 2018; 94:5004848. [PMID: 29846574 PMCID: PMC5995215 DOI: 10.1093/femsec/fiy095] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Accepted: 05/24/2018] [Indexed: 11/12/2022] Open
Abstract
The development and activity of a cold-adapting microbial community was monitored during low-temperature anaerobic digestion (LtAD) treatment of wastewater. Two replicate hybrid anaerobic sludge bed-fixed-film reactors treated a synthetic sewage wastewater at 12°C, at organic loading rates of 0.25-1.0 kg chemical oxygen demand (COD) m-3 d-1, over 889 days. The inoculum was obtained from a full-scale anaerobic digestion reactor, which was operated at 37°C. Both LtAD reactors readily degraded the influent with COD removal efficiencies regularly exceeding 78% for both the total and soluble COD fractions. The biomass from both reactors was sampled temporally and tested for activity against hydrolytic and methanogenic substrates at 12°C and 37°C. Data indicated that significantly enhanced low-temperature hydrolytic and methanogenic activity developed in both systems. For example, the hydrolysis rate constant (k) at 12°C had increased 20-30-fold by comparison to the inoculum by day 500. Substrate affinity also increased for hydrolytic substrates at low temperature. Next generation sequencing demonstrated that a shift in a community structure occurred over the trial, involving a 1-log-fold change in 25 SEQS (OTU-free approach) from the inoculum. Microbial community structure changes and process performance were replicable in the LtAD reactors.
Collapse
|